Name Address/P.O. Box Postal Code/City Country Contact Person Telephone Email Website Social Media Number of Employees Founded (year) Type of Laboratory
›
› › › › › › › › › › ›
What We Do
Altasciences 575 Armand-Frappier Blvd. Laval, QC H7V 4B3 Canada Sophie Dubois +1-450-973-6077 contact@altasciences.com https://www.altasciences.com/
I +1,800 1992 Full-service CRO/CDMO offering comprehensive range of preclinical, clinical, bioanalytical, and CDMO services.
Areas of Activity
›
Preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, drug formulation and manufacturing, programme management, medical writing, biostatistics, and data management.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions to offer pharmaceutical and biotechnology companies a proven, integrated approach to preclinical and clinical pharmacology studies, including bioanalysis, formulation, manufacturing, and analytical services. Our comprehensive, full-service solutions are customisable to specific sponsor requirements. With eight locations across North America, Altasciences helps sponsors get better drugs to the people who need them, faster.
Who We Are For over 25 years, our Altascientists have been partnering with drug sponsors to design the most efficient preclinical, clinical, bioanalytical, or manufacturing programmes that meet all regulatory requirements. We are committed to ensuring timely information capture, proactive communication, and smooth transitions between phases and studies.
Integrated Drug Development Solutions At Altasciences, early phase drug development is approached as a single continuum, rather than a series of separate steps. We can support your entire programme end to end, or you can partner with us for just one element — we offer complete flexibility. Our outsourcing platform enables you to work with a single, integrated partner from lead candidate selection to clinical proof of concept, and beyond. By centralising communication and scheduling using proprietary platforms as well as applying robust insights at each development stage, we help sponsors make more educated, faster, and more complete early phase drug development decisions. Our programme managers are the single point of contact for a comprehensive, full-service package designed to minimise hand-offs, resulting in shorter timelines and reduced costs. We call this Proactive Drug Development.
Member of
European Biotechnology Net work
